Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST-06
- Development stage
- Phase 1
- Lead developer
- Biosyngen
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
BST-06 is an investigational **cell therapy** under development for the treatment of advanced hepatocellular carcinoma. Early phase 1 clinical trials are underway to assess its safety, tolerability, and preliminary efficacy in patients. The therapy involves direct injection of BST06 cells, and the developer is BioSyngen. Specific details about the precise cell type, engineered features, and mechanism of action are not disclosed in public domain sources as of August 2025, but it is intended for solid tumor immunotherapy, targeting liver cancer.
- Brand names
- BST-06BST06BST 06
- Other names
- BST06BST-06BST 06
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on BST-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BST-06.